KR100840169B1 - 국소적 겔 전달 시스템 - Google Patents

국소적 겔 전달 시스템 Download PDF

Info

Publication number
KR100840169B1
KR100840169B1 KR1020037001564A KR20037001564A KR100840169B1 KR 100840169 B1 KR100840169 B1 KR 100840169B1 KR 1020037001564 A KR1020037001564 A KR 1020037001564A KR 20037001564 A KR20037001564 A KR 20037001564A KR 100840169 B1 KR100840169 B1 KR 100840169B1
Authority
KR
South Korea
Prior art keywords
composition
carbopol
corticosteroid
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037001564A
Other languages
English (en)
Korean (ko)
Other versions
KR20030057526A (ko
Inventor
다우고든제이
라쓰로프로버트더블유
다우데브라에이
Original Assignee
다우 파마슈티컬 사이언시즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24535786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100840169(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다우 파마슈티컬 사이언시즈 filed Critical 다우 파마슈티컬 사이언시즈
Publication of KR20030057526A publication Critical patent/KR20030057526A/ko
Application granted granted Critical
Publication of KR100840169B1 publication Critical patent/KR100840169B1/ko
Assigned to 다우 파마슈티컬 사이언시즈, 인코포레이티드 reassignment 다우 파마슈티컬 사이언시즈, 인코포레이티드 권리의 전부이전등록 Assignors: 다우 파마슈티컬 사이언시즈
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020037001564A 2000-08-03 2001-07-24 국소적 겔 전달 시스템 Expired - Lifetime KR100840169B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/632,508 US6387383B1 (en) 2000-08-03 2000-08-03 Topical low-viscosity gel composition
US09/632,508 2000-08-03
PCT/US2001/023341 WO2002011683A1 (en) 2000-08-03 2001-07-24 Topical gel delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087008303A Division KR20080036246A (ko) 2000-08-03 2001-07-24 국소적 겔 전달 시스템

Publications (2)

Publication Number Publication Date
KR20030057526A KR20030057526A (ko) 2003-07-04
KR100840169B1 true KR100840169B1 (ko) 2008-06-23

Family

ID=24535786

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020037001564A Expired - Lifetime KR100840169B1 (ko) 2000-08-03 2001-07-24 국소적 겔 전달 시스템
KR1020087008303A Withdrawn KR20080036246A (ko) 2000-08-03 2001-07-24 국소적 겔 전달 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087008303A Withdrawn KR20080036246A (ko) 2000-08-03 2001-07-24 국소적 겔 전달 시스템

Country Status (24)

Country Link
US (2) US6387383B1 (enExample)
EP (2) EP2052714B1 (enExample)
JP (1) JP4988129B2 (enExample)
KR (2) KR100840169B1 (enExample)
CN (2) CN1460013B (enExample)
AR (1) AR030093A1 (enExample)
AT (1) ATE429922T1 (enExample)
AU (2) AU2001279002B2 (enExample)
BE (1) BE2013C060I2 (enExample)
BR (1) BR0113247A (enExample)
CA (1) CA2417646C (enExample)
CY (3) CY1109189T1 (enExample)
DE (1) DE60138549D1 (enExample)
DK (2) DK2052714T3 (enExample)
ES (2) ES2326955T3 (enExample)
FR (1) FR14C0053I1 (enExample)
LU (1) LU92401I2 (enExample)
MX (1) MXPA03001006A (enExample)
PL (1) PL213237B1 (enExample)
PT (2) PT2052714E (enExample)
RU (1) RU2251410C2 (enExample)
SI (2) SI1304992T1 (enExample)
WO (1) WO2002011683A1 (enExample)
ZA (1) ZA200301037B (enExample)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
CZ20012038A3 (cs) 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
MXPA03009995A (es) 2001-05-09 2004-06-30 Univ Michigan Uso de composiciones para tratar rosacea.
US7368122B1 (en) * 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
WO2004000263A1 (en) 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US6906014B2 (en) * 2002-09-10 2005-06-14 Permatex, Inc. Stabilized topical composition
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
WO2004064833A1 (en) 2003-01-24 2004-08-05 Connetics Australia Pty Ltd. Clindamycin phosphate foam
CA2515293C (en) * 2003-02-07 2012-03-20 Mochida Pharmaceutical Co., Ltd. Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
WO2005018556A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
AU2003265624B2 (en) * 2003-08-21 2011-03-31 Abeona Therapeutics Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
RU2006105101A (ru) 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
WO2005027807A1 (en) 2003-09-19 2005-03-31 Drugtech Corporation Pharmaceutical delivery system
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EP1669379B1 (en) * 2003-09-23 2007-11-14 Akciju Sabiedriba "Olainfarm" 3,5-dimethyl-1-adamantyl-ammonium polymeric salts and the use thereof in the form of antiviral agents
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
US8598192B2 (en) * 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
JP5528657B2 (ja) * 2003-12-30 2014-06-25 オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド 酸化還元電位水溶液並びにその製造方法および使用方法
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20060014834A1 (en) * 2004-05-11 2006-01-19 Mohan Vishnupad Retinoid solutions and formulations made therefrom
US7662855B2 (en) * 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
US20050255131A1 (en) * 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
ES2424644T3 (es) 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
ITMI20041376A1 (it) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
DE602005021238D1 (de) * 2004-11-09 2010-06-24 Imaginative Res Associates Inc Retinoidlösungen und formulierungen daraus
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
CA2605341A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
KR20130114229A (ko) * 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
BRPI0614949A2 (pt) * 2005-08-23 2011-04-26 Nissan Chemical Ind Ltd preparação de liberação sustentada
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
KR20080083190A (ko) * 2006-01-05 2008-09-16 드러그테크 코포레이션 외음질 표면에 생체접착을 위한 약물 전달 시스템
WO2007079389A2 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Composition and method of use thereof
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
EP1998742A2 (en) * 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
BRPI0709674A2 (pt) 2006-03-31 2011-12-06 Stiefel Research Australia Pty Ltd. gel de suspensão espumante
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
RU2309738C1 (ru) * 2006-08-28 2007-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав с противовоспалительным и обезболивающим действием и способ его получения
CA2666398C (en) 2006-10-17 2015-08-18 Ed Kisak Diclofenac gel
US8466128B2 (en) 2007-01-30 2013-06-18 Cypress Pharmaceuticals, Inc. Hyaluronate compositions
US20080287373A1 (en) * 2007-05-17 2008-11-20 Popp Karl F Topical skin treating kits
US20080312245A1 (en) * 2007-06-12 2008-12-18 Longyan Xiao Methods and compositions for treating acne and other infectious diseases
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
CN101903022A (zh) * 2007-10-18 2010-12-01 梅迪奇斯医药公司 类维生素a和过氧化苯甲酰水凝胶
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2709199A1 (en) 2007-12-21 2009-07-02 Galderma Laboratories, Inc. Pre-surgical treatment
US20090176719A1 (en) * 2008-01-07 2009-07-09 Liolabs Llc Compositions and methods for treating perioral dermatitis
WO2009116086A2 (en) * 2008-03-17 2009-09-24 Glenmark Pharmaceuticals Limited Stable fixed dose topical formulation
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
MX2010012385A (es) * 2008-05-16 2010-12-02 Galderma Res & Dev Regimen de terapia para tratar enfermedades relacionadas al acne.
ES2773931T3 (es) 2008-06-05 2020-07-15 Bausch Health Ireland Ltd Formulaciones farmacéuticas tópicas que contienen una baja concentración de peróxido de benzoílo en suspensión en agua y un solvente orgánico miscible en agua
CA2728727C (en) * 2008-06-24 2018-01-23 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2440210A4 (en) * 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
US9364485B2 (en) 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
RU2587041C2 (ru) 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013019974A1 (en) 2011-08-02 2013-02-07 Medicis Pharmaceutical Corporation Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea
WO2013057579A2 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
PH12014500785A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method for treating capillary hemangiomas
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
RU2548714C2 (ru) * 2012-05-03 2015-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения угревой болезни и способ ее получения
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
RU2530644C2 (ru) * 2012-11-01 2014-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Противоугревая фармацевтическая композиция и способ ее получения
WO2014113493A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
KR102221499B1 (ko) 2013-09-26 2021-03-02 갈데르마 소시에떼아노님 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
WO2015134645A1 (en) * 2014-03-07 2015-09-11 The Procter & Gamble Company Personal care compositions comprising zinc compound and/or pyrithione
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
CN104473865A (zh) * 2014-11-17 2015-04-01 重庆华邦制药有限公司 地奈德凝胶剂及其制备方法
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
HUE050603T2 (hu) 2015-06-18 2020-12-28 Bausch Health Ireland Ltd Egy kortikoszteroidot és egy retinoidot tartalmazó topikális készítmények psoriasis kezelésére
EP3322401A1 (en) 2015-07-13 2018-05-23 Dr. Reddy's Laboratories Ltd. Topical retinoid compositions
CN106474059A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的地奈德洗剂
CN106474047A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种对光稳定的地奈德制剂
CN106474048A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的地奈德凝胶制剂
AU2017241767B2 (en) 2016-03-28 2021-07-22 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
US11812939B2 (en) 2017-05-15 2023-11-14 Cornell University Device and system for repairing intervertebral disc herniation and methods of use
US10779525B2 (en) 2018-01-16 2020-09-22 Zin Research LLC Treatment compound and method of application for hoof or foot disease in animals
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
US20200138822A1 (en) * 2018-11-06 2020-05-07 Tim COTE Topical compositions comprising pentoxifylline and methods of treatment using the same
FR3090385B1 (fr) * 2018-12-21 2021-01-08 Pf Medicament Composition émolliente sous forme d’émulsion
CN111743853A (zh) * 2019-03-29 2020-10-09 天津金耀集团有限公司 一种近中性丁酸氢化可的松的外用药物组合物
CN114126582A (zh) 2019-08-01 2022-03-01 博世健康爱尔兰有限公司 局部用组合物
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
US20220202841A1 (en) * 2020-12-24 2022-06-30 Erine A. Kupetsky Dermatological formulations for treatment of dermatitis
WO2022138826A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩を含有する塗布投与用医薬組成物
CN116723865A (zh) * 2021-01-29 2023-09-08 花王株式会社 外用剂组合物
IL313866A (en) * 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
CA3255435A1 (en) 2022-05-20 2023-11-23 Dermbiont, Inc. Compositions and formulations allowing the use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders
CN116098702A (zh) * 2023-02-03 2023-05-12 上海微创微航机器人有限公司 支气管镜移动控制方法、系统及介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969516A (en) * 1974-12-19 1976-07-13 Nelson Research & Development Company Composition and method for treatment of acne
US4497794A (en) 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US4361584A (en) 1977-10-07 1982-11-30 A.H.C. Pharmacal, Inc. Composition and method for the treatment of acne
US4247547A (en) 1979-03-19 1981-01-27 Johnson & Johnson Tretinoin in a gel vehicle for acne treatment
US4387107A (en) 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4692329A (en) 1980-12-08 1987-09-08 William H. Rorer, Inc. Erythromycin/benzoyl peroxide antiacne compositions
LU83173A1 (fr) 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
US4514385A (en) 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
CH643138A5 (de) * 1983-08-29 1984-05-30 Mepha Ag Indomethacin enthaltende, gelartige salbe.
LU85111A1 (fr) 1983-12-01 1985-09-12 Oreal Composition anti-acnetique a base de peroxyde de benzoyle et d'au moins un filtre solaire
US4670254A (en) * 1983-12-09 1987-06-02 Toko Yakuhin Industry Co., Ltd. Gel preparations for topical application of diclofenac sodium
US5446028A (en) 1985-12-12 1995-08-29 Dermik Laboratories, Inc. Anti-acne method and composition
FR2604357B1 (fr) 1986-09-30 1988-12-02 Oreal Composition pharmaceutique et cosmetique anti-acneique
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
DE3773383D1 (de) * 1987-03-20 1991-10-31 Curatek Pharmaceuticals Neue topische metronidazol-formulierungen.
MY105521A (en) * 1989-04-17 1994-10-31 Healthpoint Ltd Moisturizing vehicle for topical application of vitamin a acid.
DE69029804T2 (de) 1989-06-07 1997-09-04 Gail S Bazzano VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
GB9021320D0 (en) 1990-10-01 1990-11-14 Diomed Dev Ltd Compositions for topical application
US5380528A (en) 1990-11-30 1995-01-10 Richardson-Vicks Inc. Silicone containing skin care compositions having improved oil control
JP3555762B2 (ja) * 1991-10-16 2004-08-18 リチャードソン、ビックス、インコーポレーテッド 非イオン性ポリアクリルアミド誘導体を含有した低ｐＨ水性化粧品ゲル
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
US5549914A (en) * 1992-12-14 1996-08-27 Sween Corporation Heat stable wound care gel
RO115109B1 (ro) 1993-07-01 1999-11-30 Yamanouchi Europ Bv Compozitie stabila cu retinoid
US5482710A (en) 1993-07-30 1996-01-09 Chesebrough-Pond'usa Co., Division Of Conopco, Inc. Cosmetic composition for treatment of pimples and redness
US5382432A (en) 1993-11-15 1995-01-17 Elizabeth Arden Company, Division Of Conopco, Inc. Cosmetic method for treatment of skin
US5466446A (en) 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
WO1995025544A1 (en) * 1994-03-21 1995-09-28 John Brown Thomsen Gel for treatment of skin diseases and for disinfection of the skin
US5538732A (en) 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
US5445823A (en) 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5750122A (en) 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
JP3193617B2 (ja) * 1996-01-29 2001-07-30 カネボウ株式会社 清涼感付与剤および人体用組成物
US5891451A (en) 1996-06-25 1999-04-06 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters
RU2119329C1 (ru) * 1996-06-26 1998-09-27 Акционерное общество открытого типа "Щелковское предприятие Агрохим" Основа для репеллентных кремов
FR2753626B1 (fr) * 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
JPH1179948A (ja) * 1997-09-12 1999-03-23 Noevir Co Ltd 養毛剤及び毛髪用化粧料、並びに皮脂分泌抑制用皮膚外用剤
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
국제공개특허공보 제99/22716호*

Also Published As

Publication number Publication date
AU2001279002B2 (en) 2006-04-27
KR20080036246A (ko) 2008-04-25
LU92401I2 (fr) 2014-05-19
EP1304992A4 (en) 2006-11-02
DK1304992T3 (da) 2009-08-10
CN101305982B (zh) 2011-12-14
MXPA03001006A (es) 2005-02-25
CN1460013A (zh) 2003-12-03
EP2052714A1 (en) 2009-04-29
CY1109189T1 (el) 2014-07-02
ES2437321T3 (es) 2014-01-10
CA2417646A1 (en) 2002-02-14
ZA200301037B (en) 2004-02-09
ES2326955T3 (es) 2009-10-22
JP2004505900A (ja) 2004-02-26
DK2052714T3 (da) 2013-10-14
CN101305982A (zh) 2008-11-19
BR0113247A (pt) 2003-06-24
PT2052714E (pt) 2013-10-17
FR14C0053I1 (fr) 2014-08-08
EP2052714B1 (en) 2013-09-04
US20020176891A1 (en) 2002-11-28
AR030093A1 (es) 2003-08-13
JP4988129B2 (ja) 2012-08-01
HK1125847A1 (en) 2009-08-21
WO2002011683A1 (en) 2002-02-14
EP1304992A1 (en) 2003-05-02
SI1304992T1 (sl) 2009-10-31
AU7900201A (en) 2002-02-18
US6387383B1 (en) 2002-05-14
PL360589A1 (pl) 2004-09-06
CA2417646C (en) 2010-05-04
RU2251410C2 (ru) 2005-05-10
ATE429922T1 (de) 2009-05-15
EP1304992B1 (en) 2009-04-29
KR20030057526A (ko) 2003-07-04
CN1460013B (zh) 2011-12-14
US6517847B2 (en) 2003-02-11
CY2014005I1 (el) 2014-07-02
BE2013C060I2 (enExample) 2020-12-15
DE60138549D1 (de) 2009-06-10
CY2014005I2 (el) 2015-12-09
PL213237B1 (pl) 2013-01-31
CY1114646T1 (el) 2016-12-14
PT1304992E (pt) 2009-07-20
SI2052714T1 (sl) 2013-11-29

Similar Documents

Publication Publication Date Title
US6387383B1 (en) Topical low-viscosity gel composition
AU2001279002A1 (en) Topical gel delivery system
AU666169B2 (en) Compositions of clindamycin and benzoyl peroxide for acne treatment
US6117843A (en) Compositions for the treatment of acne containing clindamycin and benzoyl peroxide
US4247547A (en) Tretinoin in a gel vehicle for acne treatment
US7368122B1 (en) Skin cream
US9937134B2 (en) Hyaluronate compositions
US20070003585A1 (en) Topical skin treating compositions
US20100210571A1 (en) Topical formulations for treatment of skin disorders
KR20090028764A (ko) 여드름 병변 치료를 위한 아다팔렌 및 벤조일 퍼옥시드의 조합물
US20040167223A1 (en) Topical antibacterial formulations
US20040171561A1 (en) Topical formulations for treatment of rosacea
HK1125847B (en) Topical gel delivery system
RU2548714C2 (ru) Фармацевтическая композиция для лечения угревой болезни и способ ее получения
JP2023026516A (ja) 油性外用液
Thielitz et al. Topical Retinoids
CA2586798A1 (en) Retinoid solutions and formulations made therefrom

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030203

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060721

Comment text: Request for Examination of Application

AMND Amendment
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070727

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080204

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070727

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080306

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080204

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080422

Appeal identifier: 2008101001901

Request date: 20080306

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080404

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080404

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080306

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071026

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070405

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20060724

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20060721

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20030701

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20080422

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20080415

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080616

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080616

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110609

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120518

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130522

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130522

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140610

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140610

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150605

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150605

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160330

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20170330

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20220124

Termination category: Expiration of duration